Katia Mancuso

17PUBLICATIONS
67CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nanomedicine
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Mar 11, 2026
Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real-World Evidence in a Rapidly Evolving Therapeutic Landscape.

K Mancuso, S Masci, M Talarico

|Aug 14, 2025
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. Cancers 2025, 17, 1168.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

|May 14, 2025
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS.

Katia Mancuso, Marco Talarico, Enrica Manzato

|Apr 14, 2025
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma.

Katia Mancuso, Simona Barbato, Francesco Di Raimondo

|Mar 19, 2025
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.

Fortunato Morabito, Enrica Antonia Martino, Monica Galli

|Feb 03, 2025
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.

Enrica Antonia Martino, Daniele Derudas, Elena Rossi

Pageof 3

Frequent Collaborators

10 joint publications

Elena Zamagni

6 joint publications

Michele Cavo

6 joint publications

Simona Barbato

5 joint publications

Ilaria Rizzello